Perspective Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 26, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 26, 2025

CATX$0.79-8.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(Dollars and shares in thousands, except for per-share amounts)

	Year Ended December 31,
2024 · 2023
Grant revenue	$1,454		$1,434
Operating expenses:
Research and development	41,638		21,311
General and administrative	26,613		21,064
Goodwill impairment	24,062		-
Loss on disposal of property and equipment	27		-
Total operating expenses	92,340		42,375
Operating loss	(90,886)		(40,941)
Non-operating income (expense):
Interest income	10,515		934
Interest and other expense, net	(48)		(82)
Equity in loss of affiliate	(8)		(17)
Total non-operating income, net	10,459		835
Net loss from continuing operations	(80,427)		(40,106)
Net loss from discontinued operations	(949)		(9,053)
Net loss before deferred income tax benefit	(81,376)		(49,159)
Deferred income tax benefit	2,097		2,651
Net loss	$(79,279)		$(46,508)
Basic and diluted loss per share:
Loss from continuing operations1	$(1.22)		$(1.40)
Loss from discontinued operations1	(0.01)		(0.34)
Basic and diluted loss per share1	$(1.23)		$(1.74)
Weighted-average number of common shares used in computing net loss per share, basic and diluted1:	64,425		26,764
Unrealized loss on available-for-sale securities	$(51)	$	-
Comprehensive loss	$(79,330)		$(46,508)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.